Is quetiapine (Seroquel) a strong QT-interval prolonging agent?

Is Quetiapine (Seroquel) a Strong QT-Prolonging Agent?

No, quetiapine is classified as a moderate QT-prolonging agent, causing approximately 6 ms of QT prolongation on average—substantially less than high-risk antipsychotics like thioridazine (25–30 ms) or haloperidol IV (7 ms), and far below the threshold that typically triggers torsades de pointes. 1, 2

Classification and Magnitude of QT Effect

• The European Heart Journal categorizes quetiapine as having moderate QT-prolonging risk, with a mean increase of approximately 6 ms. 1, 2 This places it well below high-risk agents such as thioridazine, haloperidol (especially IV), and ziprasidone. 1, 3

• The FDA label for Seroquel states that in clinical trials, quetiapine was not associated with a persistent increase in QT intervals, though the QT effect was not systematically evaluated in a thorough QT study. 4 Post-marketing cases of QT prolongation have been reported primarily in overdose situations, in patients with concomitant illness, or when combined with other QT-prolonging medications. 4

• A 2016 thorough QT study in healthy volunteers found that 100 mg quetiapine IR produced a maximum upper-bound 95% CI for ΔΔQTcI of 13.7 ms, with a mean estimate of 10.2 ms. 5 The concentration-QTc relationship was relatively flat compared to moxifloxacin, suggesting dose-dependent but modest effects. 5

Real-World Clinical Data

• A 2024 multicenter study of 8,832 quetiapine users found a mean QTc increase of only +8.3 ± 51.8 ms, with 13.0% developing severe QT prolongation (QTc >500 ms or increase >60 ms). 6 Importantly, severe QT prolongation in quetiapine users was significantly associated with ventricular arrhythmias (OR 2.84) and sudden cardiac death (OR 2.29), but these events occurred predominantly in patients with multiple risk factors. 6

• A 2025 systematic review by the QT Interval Prolongation in Clinical Toxicology Workgroup concluded that the risk of torsades de pointes is likely overstated for quetiapine overdose, and they do not recommend continuous cardiac monitoring for acute quetiapine poisoning. 7 This contrasts sharply with their recommendations for thioridazine, amisulpride, and ziprasidone, where continuous monitoring is advised. 7

• A 2018 meta-analysis of randomized controlled trials found low-quality evidence that quetiapine is associated with QT prolongation and greater odds of torsades de pointes, especially in overdose cases. 8 However, the absolute risk remains substantially lower than with high-risk antipsychotics. 8

Comparative Risk Among Antipsychotics

• A 2023 pharmacovigilance analysis of VigiBase® (WHO's global adverse event database) found that sertindole had the highest risk of QT prolongation reporting, followed by ziprasidone and amisulpride. 9 Quetiapine was not among the highest-risk agents. 9

• First-generation antipsychotics as a class carry a 21% greater risk of QT prolongation reporting (ROR 1.21; 95% CI 1.10–1.33) compared to second-generation agents like quetiapine. 9

FDA Recommendations and Contraindications

The FDA label explicitly advises avoiding quetiapine in combination with:

• Class IA antiarrhythmics (quinidine, procainamide) 4
• Class III antiarrhythmics (amiodarone, sotalol) 4
• Other high-risk antipsychotics (ziprasidone, chlorpromazine, thioridazine) 4
• Certain antibiotics (gatifloxacin, moxifloxacin) 4
• Methadone, pentamidine, levomethadyl acetate 4

Quetiapine should also be avoided in patients with:

• History of cardiac arrhythmias (especially bradycardia) 4
• Hypokalemia or hypomagnesemia 4
• Congenital long QT syndrome 4
• Congestive heart failure or cardiac hypertrophy 4

Risk Factors That Amplify QT Prolongation

Common risk factors identified across multiple guidelines include:

• Female sex 1, 3, 6
• Age >65 years 1, 3, 6
• Baseline QTc >500 ms (absolute contraindication) 1, 3
• Hypokalemia (K⁺ <4.5 mEq/L) or hypomagnesemia 1, 3, 6
• Bradycardia or recent conversion from atrial fibrillation 1, 3
• Structural heart disease (heart failure, prior MI, LVH) 1, 3, 6
• Concomitant use of multiple QT-prolonging drugs 1, 3, 6
• Amiodarone co-administration 6

Monitoring Protocol

Baseline assessment:

• Obtain a 12-lead ECG before initiating quetiapine 1, 3
• Measure serum potassium and magnesium; correct to K⁺ >4.5 mEq/L 1, 3
• Review complete medication list for drug interactions 1, 3
• Document cardiac history, including family history of sudden death 1, 3

Follow-up monitoring:

• Repeat ECG 7–15 days after initiation or dose change 1, 3
• Recheck electrolytes regularly, especially in patients on diuretics 1, 3

Action thresholds:

• QTc ≥500 ms → discontinue quetiapine immediately 1, 3
• QTc increase >60 ms from baseline → stop quetiapine regardless of absolute value 1, 3
• QTc 450–499 ms → consider switching to aripiprazole or another low-risk agent 1

Common Pitfalls

• Failing to recognize that quetiapine's QT effect is dose-dependent and markedly amplified by co-administration of other QT-prolonging drugs. 4, 5 The flat concentration-QTc relationship means that higher doses can produce disproportionately greater prolongation in susceptible individuals. 5

• Assuming all antipsychotics carry equal QT risk. 1, 2 Quetiapine's 6-ms average increase is far below thioridazine's 25–30 ms or haloperidol IV's 7 ms. 1, 3

• Overlooking electrolyte abnormalities, which exponentially increase torsades risk even with moderate QT prolongation. 1, 3, 6 Maintain potassium >4.5 mEq/L and normalize magnesium before and during treatment. 1, 3

• Not obtaining a baseline ECG. 1, 3 Without a baseline, it is impossible to detect a >60-ms increase, which is an independent indication to stop therapy. 1, 3